These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 35740503)

  • 1. Synthetic Vulnerabilities in the KRAS Pathway.
    Roman M; Hwang E; Sweet-Cordero EA
    Cancers (Basel); 2022 Jun; 14(12):. PubMed ID: 35740503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
    Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
    Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Lethal Vulnerabilities in
    Aguirre AJ; Hahn WC
    Cold Spring Harb Perspect Med; 2018 Aug; 8(8):. PubMed ID: 29101114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Not just gRASping at flaws: finding vulnerabilities to develop novel therapies for treating KRAS mutant cancers.
    Ebi H; Faber AC; Engelman JA; Yano S
    Cancer Sci; 2014 May; 105(5):499-505. PubMed ID: 24612015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRAS: A Promising Therapeutic Target for Cancer Treatment.
    Wu HZ; Xiao JQ; Xiao SS; Cheng Y
    Curr Top Med Chem; 2019; 19(23):2081-2097. PubMed ID: 31486755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic and Predictive Value in KRAS in Non-Small-Cell Lung Cancer: A Review.
    Wood K; Hensing T; Malik R; Salgia R
    JAMA Oncol; 2016 Jun; 2(6):805-12. PubMed ID: 27100819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic synthetic lethality by targeting NOP56 and mTOR in KRAS-mutant lung cancer.
    Yang Z; Liang SQ; Zhao L; Yang H; Marti TM; Hegedüs B; Gao Y; Zheng B; Chen C; Wang W; Dorn P; Kocher GJ; Schmid RA; Peng RW
    J Exp Clin Cancer Res; 2022 Jan; 41(1):25. PubMed ID: 35039048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer.
    Knickelbein K; Zhang L
    Genes Dis; 2015 Mar; 2(1):4-12. PubMed ID: 25815366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. KRAS mutant NSCLC, a new opportunity for the synthetic lethality therapeutic approach.
    de Castro Carpeño J; Belda-Iniesta C
    Transl Lung Cancer Res; 2013 Apr; 2(2):142-51. PubMed ID: 25806225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer.
    Kim J; McMillan E; Kim HS; Venkateswaran N; Makkar G; Rodriguez-Canales J; Villalobos P; Neggers JE; Mendiratta S; Wei S; Landesman Y; Senapedis W; Baloglu E; Chow CB; Frink RE; Gao B; Roth M; Minna JD; Daelemans D; Wistuba II; Posner BA; Scaglioni PP; White MA
    Nature; 2016 Oct; 538(7623):114-117. PubMed ID: 27680702
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Untangling the KRAS mutated lung cancer subsets and its therapeutic implications.
    Ritu K; Kumar P; Singh A; Nupur K; Spalgias S; Mrigpuri P; Rajkumar
    Mol Biomed; 2021 Dec; 2(1):40. PubMed ID: 34918209
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced dependency of KRAS-mutant colorectal cancer cells on RAD51-dependent homologous recombination repair identified from genetic interactions in Saccharomyces cerevisiae.
    Kalimutho M; Bain AL; Mukherjee B; Nag P; Nanayakkara DM; Harten SK; Harris JL; Subramanian GN; Sinha D; Shirasawa S; Srihari S; Burma S; Khanna KK
    Mol Oncol; 2017 May; 11(5):470-490. PubMed ID: 28173629
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting KRAS mutant cancers by preventing signaling transduction in the MAPK pathway.
    Korzeniecki C; Priefer R
    Eur J Med Chem; 2021 Feb; 211():113006. PubMed ID: 33228976
    [TBL] [Abstract][Full Text] [Related]  

  • 14. KRAS-Mutant non-small cell lung cancer: From biology to therapy.
    Ferrer I; Zugazagoitia J; Herbertz S; John W; Paz-Ares L; Schmid-Bindert G
    Lung Cancer; 2018 Oct; 124():53-64. PubMed ID: 30268480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. KRAS Cold Turkey: Using microRNAs to target KRAS-addicted cancer.
    Jones MF; Hara T; Lal A
    RNA Dis; 2015; 2(1):. PubMed ID: 29367950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of Synergistic Drug Combinations to Target KRAS-Driven Chemoradioresistant Cancers Utilizing Tumoroid Models of Colorectal Adenocarcinoma and Recurrent Glioblastoma.
    Gupta K; Jones JC; Farias VA; Mackeyev Y; Singh PK; Quiñones-Hinojosa A; Krishnan S
    Front Oncol; 2022; 12():840241. PubMed ID: 35664781
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    Chung WJ; Daemen A; Cheng JH; Long JE; Cooper JE; Wang BE; Tran C; Singh M; Gnad F; Modrusan Z; Foreman O; Junttila MR
    Proc Natl Acad Sci U S A; 2017 Dec; 114(51):E10947-E10955. PubMed ID: 29203670
    [No Abstract]   [Full Text] [Related]  

  • 18. Metabonomics study of the effects of single copy mutant KRAS in the presence or absence of WT allele using human HCT116 isogenic cell lines.
    Varshavi D; Varshavi D; McCarthy N; Veselkov K; Keun HC; Everett JR
    Metabolomics; 2021 Nov; 17(12):104. PubMed ID: 34822010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current therapy of KRAS-mutant lung cancer.
    Ghimessy A; Radeczky P; Laszlo V; Hegedus B; Renyi-Vamos F; Fillinger J; Klepetko W; Lang C; Dome B; Megyesfalvi Z
    Cancer Metastasis Rev; 2020 Dec; 39(4):1159-1177. PubMed ID: 32548736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.
    Ricciuti B; Leonardi GC; Metro G; Grignani F; Paglialunga L; Bellezza G; Baglivo S; Mencaroni C; Baldi A; Zicari D; Crinò L
    Expert Rev Respir Med; 2016; 10(1):53-68. PubMed ID: 26714748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.